UAMC-00050

UAMC-00050 is a **novel trypsin-like serine protease inhibitor** developed by the Laboratory of Medicinal Chemistry at the University of Antwerp. It displays a well-defined multi-target inhibitory profile against serine proteases, especially tryptase and urokinase-type plasminogen activator, while exhibiting selectivity with limited inhibition of coagulation-related proteases[1][3]. UAMC-00050 acts locally when administered, notably in the colon or as ocular drops, with minimal systemic absorption[2][8]. Preclinical studies demonstrate its ability to ameliorate inflammatory parameters, improve intestinal barrier function, and reduce visceral pain in models of colitis, post-inflammatory visceral hypersensitivity, and dry eye disease[1][2][4]. Its mechanism likely involves inhibition of serine protease-mediated pathways, thereby suppressing inflammation, modulating immune responses, and potentially affecting protease-activated receptors (notably PAR2 and PAR4) and MMP-9 activation[1][4]. The agent has shown proof-of-concept efficacy for **dry eye syndrome**, ocular inflammation, inflammatory bowel diseases, and visceral pain, but has not been tested in human clinical trials[6].

Other names

benzyl (1-(bis(4-acetamidophenoxy)phosphoryl)-2-(4-guanidinophenyl)ethyl)carbamate hydrochloride